reports
Inventiva: 1 director
A director at Inventiva bought 24,700 shares at 3.295EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Inventiva Announces the Implementation of a New ATM Program
Inventiva Announces the Implementation of a New ATM Program Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement ...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Mar...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM) Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce ce jour avoir enregistré un document préalable intitulé « Form F-3 » (le « Document d’Enregistrement »), auprès de la U.S. Securities and Exchange Commission (« SEC »), aux Etats...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
Inventiva CMD outlines lanifibranor's differentiation in MASH
Yesterday, Inventiva hosted a CMD which highlighted the potential of lanifibranor in MASH. Our main takeaways are i) the number of diagnosed/treated MASH patients is on the rise, a trend that is expected to continue, ii) the future of the MASH landscape will involve combination therapies with GLP-1 likely being the backbone, and iii) lanifibranor is well positioned to reach a broader set of prescribers incl. endocrinologists thanks to its mechanism and metabolic benefits. We reiterate our € 8 TP...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 20...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announc...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liv...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025 Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3Présentation de pathologie numérique de données précliniques avec lanifibranor Daix (France), New York City (New York, United States), le 7 octobre, 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnemen...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Inventiva Appoints Andrew Obenshain as Chief Executive Officer Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds Frédéric Cren, the Company’s co-founder...
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directe...
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général Daix (France), New York City (New York, Etats-Unis), le 1er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui la nomination d’Andrew Obenshain au poste de Directeur Général, à compter du 1er octobre 2025. M. Obenshain rejoindra également le Conseil d’administration de la Socié...
- Nicholas Cortellucci
- CFA
Cantech Investment Conference: Research Booklet
We are teaming up with Cantech to publish Company Spotlight reports on the companies presenting at its conference on October 9th in Toronto. The reports aim to serve as an introduction to each company and provide a basic investment thesis. To learn more about the conference and sign up to attend, please check it out here. Companies Mentioned: Acceleware Limited Anaergia Inc. Argo Corporation Avante Corp. Baylin Technologies Inc. BeWhere Holdings Inc. BIGG Digital Assets Inc. BQE Water Inc. Cl...
BYL BAYLIN TECHNOLOGIES INC
DGI. DATA COMMUNICATIONS MANAGEMENT
YFI EDGEWATER WIRELESS SYSTEMS
ENW ENWAVE CORP.
FTG FIRAN TECHNOLOGY GROUP CORP.
STAR STAR SANITARYWARE
XX AVANTE LOGIXX
PTOTF PATRIOT ONE TECHNOLOGIES
BIGG BIGG DIGITAL ASSET
ANRG ANAERGIA INC
HITI HIGH TIDE INC
GRID TANTALUS SYSTEMS HLDG INC
AIDX HEALWELL AI INC
BQE BQE WATER INC.
SBIO SABIO HOLDINGS
TTGI INC. (SBIO)
VOL TURNIUM TECHNOLOGY GROUP INC.
MGRO VOLATUS AEROSPACE CORP
TRBE MUSTGROW BIOLOGICS CORP
TRIBE PROPERTY TECHNOLOGIES INC. (TRBE)
- Jacob Mekhael
Inventiva 1H25 holds no surprises, cash runway and topline data guidan...
Inventiva reported 1H25 results which hold no surprises, and confirmed its cash runway guidance to the end of 3Q26 and timeline for the topline readout from the phase 3 (NATiV3) trial of lanifibranor in MASH, which continues to be guided for 2H26. We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the validated MASH commercial opportunity. Given relative un...
Inventiva reports its unaudited 2025 first-half financial results and ...
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million2, following in particular the completion in April 2025 of enrolment of the Phase 3 clinical trial NATiV3 evaluating lanifibranor in patients with MASHCash runway currently planned until the end of the third quarter of 2026Revenues of €4.5 million recorded in the ...
Inventiva publie ses résultats financiers non audités du premier semes...
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme1 à 24,6 millions d’euros au 30 juin 2025Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du financement structuré pouvant atteindre 348 millions d’euros2, à la suite en particulier de la finalisation, en avril 2025, du recrutement pour l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor chez des patients atteints de MASHHorizon de trésorerie prévu jusqu’à l...
Inventiva to Host Analyst and Investor Event on October 8, 2025
Inventiva to Host Analyst and Investor Event on October 8, 2025 Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape Daix (France), New York City (New York, United States), September 24, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of ...
Inventiva organise un événement analystes et investisseurs le 8 octobr...
Inventiva organise un événement analystes et investisseurs le 8 octobre 2025 Le programme inclura une mise à jour sur son médicament candidat, lanifibranor, en amont des résultats principaux de l’étude de Phase 3 NATiV3 attendus au second semestre 2026Trois experts internationaux de renom et un représentant des patients mettront en lumière les principales les évolutions qui définissent le paysage thérapeutique de la MASH Daix (France), New York City (New York, Etats-Unis), le 24 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharm...
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
LNA Sante Sa: 2 directors
Two Directors at LNA Sante Sa sold/bought 6,900 shares at 29.000EUR. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Martin Marandon-Carlhian
- Sinan Doganli
NXI NEXITY SA CLASS A
FGA FIGEAC AERO SA
SZG SALZGITTER AG
MRN MERSEN SA
LNA LNA SANTE SA
ALTA ALTAREA SCA
G24 SCOUT24 AG
SAVE SAVENCIA SA
SAX STROEER SE & CO. KGAA
LTA ALTAMIR ACT PORTEUR
TRE TECNICAS REUNIDAS SA
BSGR B&S GROUP S.A.
AG1 AUTO1 GROUP
ANR ANSWEAR.COM
ACAG AUSTRIACARD HOLDINGS AG
HBX HBX GROUP INTERNATIONAL PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.